Genetically Modified MSCs for CLI Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for critical limb ischemia (CLI) are inadequate, with limited effective pharmaceutical or biologic therapies available, particularly for patients who are not candidates for traditional revascularization due to occluded or diffusely diseased distal vessels, leading to poor limb salvage outcomes and high amputation rates.
Innovation Solution
Development of vectors and methods using nucleic acids encoding the 165A isoform VEGF protein, combined with promoters and suicide genes, to promote angiogenesis and limb salvage through administration of isolated cells such as mesenchymal stem cells engineered to express VEGF, enhancing vascularization and wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional revascularization procedures are used, then blood flow may be restored in some patients, but treatment options are limited for patients with occluded or diffusely diseased distal vessels, leading to poor limb salvage outcomes
Solution Approach 1:
The patent uses genetically modified mesenchymal stem cells as an intermediary therapeutic agent that delivers VEGF protein directly to ischemic tissue. These cells serve as a bridge between the need for blood flow restoration and the inability to perform traditional surgical revascularization in patients with occluded distal vessels. The stem cells migrate to ischemic areas and promote angiogenesis through VEGF secretion, providing a viable treatment option where conventional approaches fail.
2Reliability
If no pharmaceutical or biologic therapies are available, then current medical needs remain unmet, but development of new therapies increases treatment complexity and cost
Solution Approach 1:
The genetically modified mesenchymal stem cells exhibit self-service characteristics by autonomously migrating to ischemic tissue sites and secreting VEGF protein in response to hypoxic conditions. The cells self-regulate their therapeutic function through endogenous hypoxia-response element (HRE) sequences that activate VEGF expression specifically in low-oxygen environments, eliminating the need for external control mechanisms and reducing overall therapy complexity.
3Productivity
If high doses of VEGF are administered to promote angiogenesis, then wound healing and vascularization improve, but risk of abnormal blood vessel formation and other side effects increases
Solution Approach 1:
The patent implements local quality control by using tissue-specific promoters (muscle promoter and endothelial cell promoter) that drive VEGF expression only in ischemic muscle and vascular tissue. This ensures high concentrations of VEGF are produced precisely where needed for angiogenesis while minimizing systemic exposure and reducing the risk of abnormal blood vessel formation in non-target tissues. The localized expression strategy maintains high productivity at the treatment site while controlling harmful effects systemically.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively promotes angiogenesis, enhances vascularization, and improves wound healing in patients with CLI, potentially reducing the need for amputations and improving quality of life by addressing the underlying ischemia.
Implementation Method 1
a nucleic acid encoding a 165A isoform VEGF protein or an equivalent thereof and a promoter that regulates expression of the nucleic acid encoding the 165A isoform VEGF
Implementation Method 2
improves wound healing in patients with CLI, potentially reducing the need for amputations
Data Source
AI summary
This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.